Navigation Links
Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
Date:6/30/2008

Prescient Medical - SECRITT I Study to Evaluate Preventive Treatment of

Potentially Life Threatening Vulnerable Plaques

ROTTERDAM, Netherlands and DOYLESTOWN, Pa., June 30 /PRNewswire/ -- An interventional cardiology team led by Professor Patrick W. Serruys successfully placed a vProtect(TM) Luminal Shield in the left anterior descending (LAD) coronary artery of a 64-year-old man at Erasmus Medical Center in Rotterdam. This case marks the start of a pilot study, known as SECRITT I, designed to evaluate the vProtect(TM) Luminal Shield as a treatment for vulnerable plaques -- atherosclerotic deposits in the coronary arteries that do not produce symptoms until they rupture with potentially fatal consequences. There are more than 500,000 sudden cardiac deaths in the US, and more than 300,000 in Europe, every year. The sudden and unexpected passing of Tim Russert, host of NBC's Meet the Press, is thought to have been the result of a vulnerable plaque rupture.

The SECRITT investigators plan to place the self-expanding vProtect(TM) Luminal Shield in 15 patients with plaques identified as vulnerable by a combination of ultrasound and optical imaging techniques. These patients will be matched with 15 controls-patients who also have non-blood-flow-limiting plaques or "lesions" that have been identified as vulnerable-who will not receive the Shield. All patients are elective patients that have been referred to the cathlab for the treatment of a major lesion impairing normal cardiac function. All 30 patients will undergo follow-up diagnostic catheterizations 6 months after the initial treatment visit, at which time their lesions will be re-evaluated. This information will enable the investigators to observe whether the Shield has stabilized the target lesions.

According to Professor Patrick W. Serruys, MD, PhD, of Erasmus University, the SECRITT I trial represents the logical extension of modern cardiac medicine: "We are very good at op
'/>"/>

SOURCE Prescient Medical
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 2015  The Pittsburgh Life Sciences Greenhouse (PLSG), the ... that one of its portfolio companies, Medrobotics Corporation, has ... Robotic System in the U.S.  ... Medrobotics," said John W. Manzetti , president and ... way since spinning out of The Robotics Institute at ...
(Date:8/4/2015)... , Aug. 4, 2015  Intec Pharma Ltd. (the ... company focused on developing drugs based on its proprietary ... its initial public offering in the United ... at a price to the public of $6.00 per ... the ordinary shares are being offered by the Company.  ...
(Date:8/4/2015)... 4, 2015 P&S Market ... overview, trends, DRO analysis, market segmentation, market size ... and top competitor profiles in: Global ... Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC on Global ...
Breaking Medicine Technology:Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... Calif., Oct. 11 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... analysis, it would stop enrollment in a Phase 2 ... patients with,recurrent, sensitive small cell lung cancer. The ... there would be,an adequate response rate to justify complete ...
... KineMed Inc., a,pathway-based drug discovery and development company, ... an investigational agent,to regenerate nerve cells in the ... and mood. The agent, part of a partnered ... behavioral test in a,preclinical model. The findings were ...
Cached Medicine Technology:Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 2Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial 3KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are ... calling a physician. In an effort to share more and better information with ... Pennsylvania to publicly share patient satisfaction ratings and comments about its doctors and ...
(Date:8/4/2015)... Louis, Missouri (PRWEB) , ... August 04, 2015 ... ... Texting (IAT) solutions, today announced that Bruce McCalley joins its executive leadership team ... track record of sales success at technology companies and expanding global markets with ...
(Date:8/4/2015)... ... August 04, 2015 , ... Montclair State University and Atlantic Health System ... its kind in New Jersey, which starting this Fall will help prepare those entering ... partnered with Atlantic Health System, one of the largest health care organizations in New ...
(Date:8/4/2015)... York (PRWEB) , ... August 04, 2015 , ... It’s ... begin to describe the customer experience inside Naimie’s Beauty Center in LA. Now MENAJI ... learn how to look better. , Naimie’s Beauty Center has been a favorite of ...
(Date:8/4/2015)... , ... August 04, 2015 ... ... HealthCenter personal health record (PHR) product has achieved Office of the National ... EHR Certification from Drummond Group. HealthCenter delivers the highest quality personal health ...
Breaking Medicine News(10 mins):Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3
... women in the Nurses' Health Study has shown that Type ... the most common form of glaucoma//, accounting for about 60 ... the July issue of the journal Ophthalmology. ,Researchers ... ,Hospital, Harvard School of Public Health and Harvard Medical School ...
... used to reduce the levels of LDL cholesterol in ... cause serious muscle// damage. ,Health Canada has ... Pravachol, Zocor, Crestor and Mevacor to include warnings and ... safety information sheets. ,Statin drug users usually ...
... including MRSA, has found its way to the markets of ... one of the few new antibiotics to come on to ... organisms have undergone mutations that enabled them to develop resistance ... MRSA, in hospitals. ,The new drug Tygacil is ...
... degeneration (AMD) is twice as common in elderly smokers as ... the elderly who ate fish at least twice weekly are ... eat fish less than once a week. ... who work at the Massachusetts Eye and Ear Infirmary, which ...
... significantly reduce the load of HIV in Africa.// ... Journal PLoS Medicine, was done on a research, published ... in heterosexual men by about 60%. Now an international ... the research, across Africa to predict the potential impact. ...
... detailing the rampant sexual abuse in NHS mental units is ... in UK eight months ago. //The report says that more ... in the last 24 months. ,The Times newspaper ... which three resulted in pregnancy. Health officials maintain that the ...
Cached Medicine News:Health News:Type 2 Diabetes Increases the Risk of Glaucoma in Women 2Health News:New Drugs To Combat Mutant Bugs 2Health News:Save your Vision with Fish Oil and Quitting Smoking 2Health News:Practise Of Male Circumcision In Africa May Reduce HIV Risks 2
Invacare 5 Oxygen Concentrator, 230 VAC - Intl....
... peptic ulcers are caused by H. pylori ... while the patient is still present with ... of waived or non-waived laboratories.,The Right Choice ... rapid H. pylori test available; helps to ...
... CHECK 02 PLUS CONCENTRATOR ANALYZER Now there ... the operating parameters necessary for performing concentrator ... ™, an efficient and cost-effective analyzer designed ... concentration (%), flow rate (L-min), and patient ...
... Exclusively for the Japanese market:, ... advanced, low-sound level, low-power-consumption, high-performance oxygen ... settings., ,Offered in an attractive, ... was specifically designed to meet the ...
Medicine Products: